DoubleTree by Hilton Hotel Zagreb, Ulica Grada Vukovara 269a, Zagreb, Croatia

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "DoubleTree by Hilton Hotel Zagreb, Ulica Grada Vukovara 269a, Zagreb, Croatia"

Transcription

1 March 5 7, 2015 DoubleTree by Hilton Hotel Zagreb, Ulica Grada Vukovara 269a, Zagreb, Croatia Organizers: MS Research Association Croatia Referral Centre for Demyelinating Diseases of the CNS, Department of Neurology University Hospital Centre Zagreb Croatian Neurological Society The meeting is under Auspices: Ministry of Health of the Republic of Croatia

2 Chairpersons V. Brinar and M. Habek Organizing Committee S. Šega, S. Butković Soldo, S. Hajnšek, B. Barun and M. Bošnjak Pašić Conference secretariat Tereza Gabelić, Ivan Adamec, Luka Crnošija Department of Neurology, University Hospital Centre Zagreb Kispatičeva 12 HR Zagreb, Croatia

3 Dear Colleagues, The 7 th Croatian International Conference on Multiple Sclerosis and Related Autoimmune Disorders, Zagreb, March 5-7, 2015, represents continuation of the previous six Dubrovnik International Conferences on Multiple Sclerosis. At this Conference, along with contemporary views on immunopathology, clinical and neuroimaging diagnosis of multiple sclerosis (MS), special attention will be focused on the treatment of MS in adults, neurophysiologic monitoring (autonomic nervous system disorders, OCT, evoked potentials, polysomnography) epidemiology of MS, importance and optimal use of cannabis treatment in MS, importance of diet environmental influences as a trigger of MS as well as on the differential diagnostic importance of similar demyelinating disorders, with special reference to autoimmune encephalitis Treatment optimization in MS is important specifically because MS is characterized by different clinical presentations and variable clinical course, however the treatment of this individually diverse disease is almost identical, especially in the early phase of the disease. Personalized approach to the treatment of MS is extremely important, but how to apply this personalized approach nowadays with emerging new therapies is still an unanswered question. Another problem is how to determine and how to treat a patient with suboptimal response? Our intention is to answer these questions and to determine the optimal method of treatment in an interactive communication with known experts in the field of MS through a variety of examples, with clear explanation of the reasons for a particular therapeutic approach. Neurophysiology nowadays is another very important parameter in monitoring development of MS. Although clinical and MRI characteristics are the mainstream in the diagnosis and disease monitoring in MS, in the past several years we have witnessed great advancement in clinical neurophysiology methods in MS. With the introduction of experimental evoked potentials, optic coherence tomography, various tests of autonomic nervous system, and polysomnography, the spectrum of MS manifestations has been broadened and we have new tools in monitoring the disease progression. Our intention is to present the characteristics and importance of the mentioned neurophysiologic tools in MS monitoring with implications on the prognosis and possible influence on the choice or even changes of treatment. Epidemiological data on MS attract special attention not only because of the increasing number of MS patients, but also because in recent years we are witnessing enormous advances in the epidemiology of MS, most of all, the importance of vitamin D in MS. What is better, to recommend taking high doses of vitamin D or to exercise in the sun, or both? Is there a connection between MS and different dietary habits? Our intention is to answer such questions with well-known experts in the field of MS epidemiology. Other demyelinating diseases of the CNS also represent very important diagnostic and therapeutic problems. It is well known that, although MS is the most common demyelinating disease of the CNS, we often encounter white matter changes in patients with atypical clinical symptoms such as headache, fatigue or functional disturbances. What would be the optimal diagnostic algorithm in such conditions often diagnosed as inflammatory or ischemic leukoencephalopathy? And another very important issue is how to diagnose, define and treat autoimmune encephalitis? Our intention is to answer these questions with experts in the field of autoimmune encephalitis and differential diagnosis of various demyelinating diseases. For the Organizing Committee: Vesna V. Brinar and Mario Habek

4 PROGRAM Thursday, March 5 08:00 09:30 Registration 09:30 09:45 Opening remarks V. Brinar, M. Habek 09:45 10:30 Welcome Neurophysiology of multiple sclerosis 09:45 10:30 Chairpersons: M. Habek, L. Leoncani, E. S. Papathanasiou :40 Introduction M. Habek 10:40 11:10 Neurophysiological techniques in multiple sclerosis: are they still useful? L. Leocani 11:10 11:40 Why is autonomic nervous system important in multiple sclerosis? M. Habek 11:40 12:10 Evoked potentials in monitoring disease progression in multiple sclerosis with special emphasis on VEMPs E.S. Papathanasiou 12:10 12:25 Discussion 12:25 14:00 Lunch 14:00 14:30 The VEMP score: a novel method for detection of brainstem dysfunction in multiple sclerosis T. Gabelić 14:30 15:00 Polysomnographic features in structure of sleep in multiple sclerosis patients B. Barun 15:00 15:10 Discussion 15:10 16:00 Coffee break Chairpersons: I. Adamec, B. Barun 16:00 16:30 Immunopathology of multiple sclerosis H. Lassmann 16:30 17:00 Epidemiology of multiple sclerosis M. Pugliatti 17:00 17:15 Discussion Friday, March 6 Therapy of multiple sclerosis 09:45 10:30 Chairpersons: V. Brinar, M. Linnebank, S. Šega 08:30 08:40 Introduction S. Šega 08:40 09:20 Overview of present multiple sclerosis therapy B. Kieseier 09:20 09:50 Tecfidera in MS treatment M. Linnebank 09:50 10:20 Treatment Optimization in MS R. Nicholas (sponsored by Medis/Biogen) 10:20 11:00 Coffee break 11:00 11:30 Is it time to change our views in treatment of RRMS? V. Brinar 11:30 12:20 MS therapy: an expert view interactive presentation B. Kieseier 12:20 14:20 Lunch 13:20 14:20 Poster session Presidents: I. Adamec, B. Barun, T. Gabelić 14:20 14:50 History and clinical experiences with Alemtuzumab J. Jones

5 14:50 15:20 Efficacy and effectiveness of Alemtuzumab choosing appropriate patient E. Havrdova 15:20 15:50 Aubagio From clinical trial to real world experience A. Chan 15:50 16:45 Round table discussion Chair: M. Linnebank; Moderator: E. Havrdova 16:45 17:20 Coffee break 17:20 18:00 Cannabinoid treatment in multiple sclerosis C. S. Constantinescu 20:00 22:00 Gala dinner Saturday, March 7 Environmental causes, diet and differential diagnosis of MS Chairpersons: S. Šega, M. Bošnjak Pašić, J. Drulović 08:30 08:40 Introduction V. Brinar 08:40 09:10 Pain in multiple sclerosis V. Bašić Kes 09:10 09:40 Environmental risk factors in multiple sclerosis J. Drulović 09:40 10:10 Diet and vitamin D in multiple sclerosis K. Munger 10:10 10:25 Discussion 10:25 11:00 Coffee break Differential diagnosis of multiple sclerosis 11:00 11:30 Autoimmune encephalitis F. Graus 11:30 12:00 Neuromyelitis optica and beyond I. Adamec 12:00 13:00 Interactive case presentations: differential diagnosis of multiple sclerosis M. Habek, V. Brinar 13:00 13:30 Discussion 13:30 13:45 Closing remarks 13:45 14:30 Goodbye buffet Social events: Thursday March 5, :45 10:30 Welcome buffet Friday March 6, :00 Gala Dinner Saturday March 7, :45 14:30 Goodbye buffet

6 Registration fee for participants include: Participation in scientific sessions Entrance to the exhibitions Conference program and Abstracts Books Welcome cocktail and dinner on Friday evening Coffee during breaks Lunch and Goodbye buffet Cancellation Policy No refund on cancellations after February 16, 2015 Registration/Hospitality/Information Registration desk is situated at the Hotel Double Tree by Hilton for duration of the Conference Registration will be opened on Thursday 5th of March 2015 from 8:00 and on Friday 6th from 8:30 throughout the sessions. Language The official language of the Conference will be English Power point Preview session hall will be equipped with an overhead and Power Point. Speakers should check their presentations no later than 30 minutes prior to beginning of the session. Notes:

7

8

The Nuts and Bolts of Multiple Sclerosis. Rebecca Milholland, M.D., Ph.D. Center for Neurosciences

The Nuts and Bolts of Multiple Sclerosis. Rebecca Milholland, M.D., Ph.D. Center for Neurosciences The Nuts and Bolts of Multiple Sclerosis Rebecca Milholland, M.D., Ph.D. Center for Neurosciences Objectives Discuss which patients are at risk for Multiple Sclerosis Discuss the diagnostic criteria for

More information

MNNP 3 rd Annual Fall Conference 2011 Nurse Practitioners: Promoting a Healthy Future

MNNP 3 rd Annual Fall Conference 2011 Nurse Practitioners: Promoting a Healthy Future Nurse Practitioners: Promoting a Healthy Future Conference overview Minnesota Nurse Practitioners (MNNP) cordially invite you to attend our 3 rd Annual Conference. This conference kicks off National Nurse

More information

Mellen Center for Multiple Sclerosis

Mellen Center for Multiple Sclerosis Mellen Center Cleveland Clinic Marie Namey, RN, MSN, MSCN Mellen Center Cleveland Clinic Cleveland, OH Home of. Mellen Center for Multiple Sclerosis Mellen Center Mission The Mellen Center remains committed

More information

Neurological Disorders Summit

Neurological Disorders Summit Neurological Disorders Summit July 2015 06-08 San Francisco USA Welcome Message United Scientific Group takes great pleasure in inviting you to participate at the Neurological Disorders Summit (), July

More information

Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS?

Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS? Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS? Marie Trad, M.D., Lynne Hughes, Cathy VanBelle, Amy Del Medico 3rd International

More information

MS: from disease management to patient management

MS: from disease management to patient management 2012 CME Annual meeting in multiple sclerosis MS: from disease management to patient management Valencia, Spain 18-19 May 2012 Dear Colleague On behalf of the Serono Symposia International Foundation we

More information

IPMSC First Scientific Conference Daily Program

IPMSC First Scientific Conference Daily Program IPMSC First Scientific Conference Daily Program February 6 th 2013 19:30 Welcome dinner at the NH Milano 2 Hotel February 7 th 2013 Meeting Venue: San Raffaele Congress Centre - Caravella Santa Maria Room

More information

Department of Neurology and Neurosurgery Clinical and Clinical Research Fellowship Application Form

Department of Neurology and Neurosurgery Clinical and Clinical Research Fellowship Application Form Department of Neurology and Neurosurgery Clinical and Clinical Research Fellowship Application Form Fellowship in Multiple Sclerosis and Neuroinflammatory Disorders Type of Fellowship: Clinical Research

More information

AUBAGIO (teriflunomide) oral tablet

AUBAGIO (teriflunomide) oral tablet AUBAGIO (teriflunomide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

OHTAC Recommendation

OHTAC Recommendation OHTAC Recommendation Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency Presented to the Ontario Health Technology Advisory Committee in May 2010 May 2010 Issue Background A review on the

More information

Biogen Global Medical Grants Office Multiple Sclerosis: Areas of Interest

Biogen Global Medical Grants Office Multiple Sclerosis: Areas of Interest Biogen Global Medical Grants Office Multiple Sclerosis: Areas of Interest Cycle C June 2, 2015 1 Introduction The landscape for the treatment of relapsing Multiple Sclerosis (MS) has quickly evolved over

More information

register online now! Correlating Neuroanatomy with Patient Presentation and the Neurologic Exam October 11, 2014 Course Director:

register online now! Correlating Neuroanatomy with Patient Presentation and the Neurologic Exam October 11, 2014 Course Director: Correlating Neuroanatomy with Patient Presentation and the Neurologic Exam October 11, 2014 Gonda Building, Geffen Auditorium Rochester, Minnesota Course Director: Heidi Dunfee, PT, DScPT http://pmr.education-registration.com/register/listing/598

More information

DEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE

DEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE 1 DEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE ASSESSMENT/PROBLEM RECOGNITION 1. Did the staff and physician seek and document risk factors for depression and any history of depression? 2. Did staff

More information

Wellness for People with MS: What do we know about Diet, Exercise and Mood And what do we still need to learn? March 2015

Wellness for People with MS: What do we know about Diet, Exercise and Mood And what do we still need to learn? March 2015 Wellness for People with MS: What do we know about Diet, Exercise and Mood And what do we still need to learn? March 2015 Introduction Wellness and the strategies needed to achieve it is a high priority

More information

Clinical Trials of Disease Modifying Treatments

Clinical Trials of Disease Modifying Treatments MS CENTER CLINICAL RESEARCH The UCSF MS Center is an internationally recognized leader in multiple sclerosis clinical research. We conduct clinical trials involving the use of experimental treatments,

More information

AUBMC Multiple Sclerosis Center

AUBMC Multiple Sclerosis Center AUBMC Multiple Sclerosis Center 1 AUBMC Multiple Sclerosis Center The vision of the American University of Beirut Medical Center (AUBMC) is to be the leading academic medical center in Lebanon and the

More information

Optic Neuritis. The optic nerve fibers are coated with myelin to help them conduct the electrical signals back to your brain.

Optic Neuritis. The optic nerve fibers are coated with myelin to help them conduct the electrical signals back to your brain. Optic Neuritis Your doctor thinks that you have had an episode of optic neuritis. This is the most common cause of sudden visual loss in a young patient. It is often associated with discomfort in or around

More information

2016 Pre-LACTRIMS Conference. 16 November, Buenos Aires, Argentina

2016 Pre-LACTRIMS Conference. 16 November, Buenos Aires, Argentina regional conference preliminary programme 2016 Pre-LACTRIMS Conference 16 November, 2016 - Buenos Aires, Argentina 2016 Pre-LACTRIMS Conference Overview Multiple Sclerosis (MS) is the most common demyelinating

More information

Committee Approval Date: December 12, 2014 Next Review Date: December 2015

Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January

More information

Issues Regarding Use of Placebo in MS Drug Trials. Peter Scott Chin, MD Novartis Pharmaceuticals Corporation

Issues Regarding Use of Placebo in MS Drug Trials. Peter Scott Chin, MD Novartis Pharmaceuticals Corporation Issues Regarding Use of Placebo in MS Drug Trials Peter Scott Chin, MD Novartis Pharmaceuticals Corporation Context of the Guidance The draft EMA Guidance mentions placebo as a comparator for superiority

More information

Ocular Surface Diseases Course 2016 MIAMI,FLORIDA. Bascom Palmer Eye Institute. Sponsored by the University of Miami Miller School of Medicine

Ocular Surface Diseases Course 2016 MIAMI,FLORIDA. Bascom Palmer Eye Institute. Sponsored by the University of Miami Miller School of Medicine Ocular Surface Diseases Course 2016 Bascom Palmer Eye Institute Sponsored by the University of Miami Miller School of Medicine MIAMI,FLORIDA April 16, 2016 BASCOM PALMER EYE INSTITUTE Ocular Surface Diseases

More information

Integrating New Treatments: A Case Based Approach

Integrating New Treatments: A Case Based Approach Integrating New Treatments: A Case Based Approach JILL CONWAY, MD, MA, MSCE DIRECTOR, MS CENTER DIRECTOR, NEUROLOGY CLERKSHIP AT UNCSOM- CHARLOTTE CAMPUS CAROLINAS HEALTHCARE CENTER Objectives Provide

More information

29 January 2016 - Rome, Italy

29 January 2016 - Rome, Italy Updates on MS treatment management 29 January 2016 - Rome, Italy Aims The multiple sclerosis (MS) treatment scenario is rapidly changing. New drugs are now or will be soon at disposal of clinicians allowing

More information

PCORI Workshop on Treatment for Multiple Sclerosis. Breakout Group Topics and Questions Draft 3-27-15

PCORI Workshop on Treatment for Multiple Sclerosis. Breakout Group Topics and Questions Draft 3-27-15 PCORI Workshop on Treatment for Multiple Sclerosis Breakout Group Topics and Questions Draft 3-27-15 Group 1 - Comparison across DMTs, including differential effects in subgroups Consolidated straw man

More information

TITLE: Treatment of Patients with Multiple Sclerosis: A Review of Guidelines

TITLE: Treatment of Patients with Multiple Sclerosis: A Review of Guidelines TITLE: Treatment of Patients with Multiple Sclerosis: A Review of Guidelines DATE: 13 March 2013 CONTEXT AND POLICY ISSUES Multiple sclerosis (MS) is an unpredictable, often disabling disease of the central

More information

Voting for your top research questions Survey

Voting for your top research questions Survey MS Priority Setting Partnership Voting for your top research questions Survey Prioritising important research questions for multiple sclerosis a partnership between people affected by MS and healthcare

More information

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January

More information

Accuracy in Space and Time: Diagnosing Multiple Sclerosis. 2012 Genzyme Corporation, a Sanofi company.

Accuracy in Space and Time: Diagnosing Multiple Sclerosis. 2012 Genzyme Corporation, a Sanofi company. Accuracy in Space and Time: Diagnosing Multiple Sclerosis 2012 Genzyme Corporation, a Sanofi company. Brought All rights to reserved. you by www.msatrium.com, MS.US.PO876.1012 your gateway to MS knowledge.

More information

43. MULTIPLE SCLEROSIS

43. MULTIPLE SCLEROSIS Guidelines to be followed by centres, services and units in order to be designated as Reference Centres, Services and Units of the National Health System, as agreed by the Interterritorial Board 43. MULTIPLE

More information

MULTIPLE SCLEROSIS AUSTRALIA MULTIPLE SCLEROSIS RESEARCH AUSTRALIA

MULTIPLE SCLEROSIS AUSTRALIA MULTIPLE SCLEROSIS RESEARCH AUSTRALIA MULTIPLE SCLEROSIS AUSTRALIA MULTIPLE SCLEROSIS RESEARCH AUSTRALIA Submission to the ACT Legislative Assembly Health, Ageing, Community and Social Services Inquiry into the exposure draft of the Drugs

More information

Treatment Programs (OMTP)

Treatment Programs (OMTP) Sponsored by: Continuing Medical Education Program best practices for Opiate Maintenance Treatment Programs (OMTP) Avoid Abuse, Limit Liability May 8-11, 2012 December 4-7, 2012 Case Western Reserve University

More information

New perception of disability including cognition, fatigue, pain and other impairments related to MS

New perception of disability including cognition, fatigue, pain and other impairments related to MS New perception of disability including cognition, fatigue, pain and other impairments related to MS Diego Cadavid, MD Director, MS Clinical Development Biogen Idec 1 Need for clarity on terminology for

More information

Genzyme s Multiple Sclerosis Franchise Featured at AAN

Genzyme s Multiple Sclerosis Franchise Featured at AAN PRESS RELEASE Genzyme s Multiple Sclerosis Franchise Featured at AAN - Multiple Presentations Highlight Continuing Progress of AUBAGIO and LEMTRADA Programs - Paris, France March 13, 2013 Sanofi (EURONEXT:

More information

Multiple Sclerosis Fellowship Neurology Department University of Texas Southwestern Medical School 5323 Harry Hines Blvd., Dallas, TX 75390-8806

Multiple Sclerosis Fellowship Neurology Department University of Texas Southwestern Medical School 5323 Harry Hines Blvd., Dallas, TX 75390-8806 Multiple Sclerosis Fellowship Neurology Department University of Texas Southwestern Medical School 5323 Harry Hines Blvd., Dallas, TX 75390-8806 Program Director: Elliot M Frohman, MD, PhD., FAAN Information

More information

CNS DEMYLINATING DISORDERS

CNS DEMYLINATING DISORDERS CNS DEMYLINATING DISORDERS Multiple sclerosis A Dutch saint named Lidwina, who died in 1433, may have been one of the first known MS patients. After she fell while ice skating, she developed symptoms such

More information

FastTest. You ve read the book... ... now test yourself

FastTest. You ve read the book... ... now test yourself FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to

More information

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

More information

Nordic Congres of Clinical Neurophysiology

Nordic Congres of Clinical Neurophysiology Nordic Congres of Clinical Neurophysiology 7-9 th of May 2015 Hotel Marienlyst, Helsingør, Denmark Webside: www.nccn2015.dk Scientific programme Thursday May 7 th 11:00 11:05 Welcome 11:05 12:30 New neurophysiological

More information

MRI in Differential Diagnosis

MRI in Differential Diagnosis MRI in Differential Diagnosis Jill Conway, MD, MA, MSCE Director, Carolinas MS Center Clerkship Director, UNCSOM-Charlotte Campus Charlotte, NC DISCLOSURES Speaking, consulting, and/or advisory boards

More information

Medication Policy Manual. Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014

Medication Policy Manual. Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014 Medication Policy Manual Policy No: dru376 Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective

More information

2014 ALUMNI ALUMNI. 134th Anniversary ASSOCIATION. MAY 16-18, 2014 New York Marriott at the Brooklyn Bridge COLLEGE OF MEDICINE

2014 ALUMNI ALUMNI. 134th Anniversary ASSOCIATION. MAY 16-18, 2014 New York Marriott at the Brooklyn Bridge COLLEGE OF MEDICINE ALUMNI ASSOCIATION COLLEGE OF MEDICINE SUNY Downstate Medical Center 134th Anniversary 2014 ALUMNI MAY 16-18, 2014 New York Marriott at the Brooklyn Bridge Payment Information o Dinner Dance AND Journal

More information

A Definition of Multiple Sclerosis

A Definition of Multiple Sclerosis English 182 READING PRACTICE by Alyx Meltzer, Spring 2009 Vocabulary Preview (see bolded, underlined words) gait: (n) a particular way of walking transient: (adj) temporary; synonym = transitory remission:

More information

Invitation to Host Academy Event

Invitation to Host Academy Event Invitation to Host Academy Event You are invited to host a conference or congress of the Future Academy. If you are interested in serving as host, please complete and sign the attached application form,

More information

Multiple Sclerosis. Matt Hulvey BL A - 615

Multiple Sclerosis. Matt Hulvey BL A - 615 Multiple Sclerosis Matt Hulvey BL A - 615 Multiple Sclerosis Multiple Sclerosis (MS) is an idiopathic inflammatory disease of the central nervous system (CNS) MS is characterized by demyelination (lesions)

More information

Sponsor packages. 3rd EABA and EC Algae Contractors Conference, and the 10th International Algae Congress 6-8 December 2016 / Madrid, Spain

Sponsor packages. 3rd EABA and EC Algae Contractors Conference, and the 10th International Algae Congress 6-8 December 2016 / Madrid, Spain Sponsor packages 3rd EABA and EC Algae Contractors Conference, and the 10th International Algae Congress 6-8 December 2016 / Madrid, Spain Targeted visibility at Europe s largest algae platform Key Features

More information

Chapter 4 Health Care Management Unit 1: Care Management

Chapter 4 Health Care Management Unit 1: Care Management Chapter 4 Health Care Unit 1: Care In This Unit Topic See Page Unit 1: Care Care 2 6 Emergency 7 4.1 Care Healthcare Healthcare (HMS), Highmark Blue Shield s medical management division, is responsible

More information

Legal Forum Summer 2014 Sponsorship Opportunities

Legal Forum Summer 2014 Sponsorship Opportunities Legal Forum Summer 2014 Sponsorship Opportunities For more information visit www.mlmeeting.com 1 Welcome Cocktail Reception Sponsor Wednesday Night Expenses for the cocktail party will be the responsibility

More information

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January

More information

The Copernican Revolution in Ischemic Heart Diseases: the day after

The Copernican Revolution in Ischemic Heart Diseases: the day after Menarini Foundation Symposia: 249 The Copernican Revolution in Ischemic Heart Diseases: the day after Pisa (Italy), June 27 th 28 th, 2014 Organized by POSTGRADUATE SCHOOL OF CARDIOVASCULAR MEDICINE UNIVERSITY

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website. It is provided for patients and healthcare professionals to increase the transparency of

More information

AANN ADVANCES IN STROKE CARE CONFERENCE

AANN ADVANCES IN STROKE CARE CONFERENCE AANN ADVANCES IN STROKE CARE CONFERENCE September 25 26, 2015 Hilton Rosemont/Chicago O Hare Chicago, IL AANN.org/strokeconference Earn up to 15 contact hours! ANSWERING YOUR CALL FOR MORE STROKE KNOWLEDGE

More information

What Really Works in Educational Simulations for Healthcare. Sponsored by:

What Really Works in Educational Simulations for Healthcare. Sponsored by: What Really Works in Educational Simulations for Healthcare Sponsored by: Purpose The Health Education Research Technology Unit (HETRU) is proud to present an important and timely conference: What Really

More information

13 September 2016 - London, UK

13 September 2016 - London, UK INTERNATIONAL WORKSHOP PRELIMINARY PROGRAMME MS Academia: Multiple sclerosis advanced course 13 September 2016 - London, UK MS Academia - Multiple sclerosis advanced course Overview Multiple sclerosis

More information

J.P. Morgan Cazenove Therapeutic Seminar

J.P. Morgan Cazenove Therapeutic Seminar Jannan, MS J.P. Morgan Cazenove Therapeutic Seminar David Meeker - CEO, Genzyme June 25, 2012 Forward Looking Statements This presentation contains forward-looking statements as defined in the Private

More information

Summary HTA. Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C. HTA-Report Summary

Summary HTA. Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C. HTA-Report Summary Summary HTA HTA-Report Summary Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C Health policy background Multiple sclerosis (MS) is a chronic inflammatory disease

More information

MS an Mental Health. Alison Carolan MS Mental Health Nurse Kings College Hospital. IMPARTS December 2013

MS an Mental Health. Alison Carolan MS Mental Health Nurse Kings College Hospital. IMPARTS December 2013 MS an Mental Health Alison Carolan MS Mental Health Nurse Kings College Hospital IMPARTS December 2013 MS and Mental Health MS is an autoimmune disease MS carries high risk of common mental disorders and

More information

1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1

1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1 1 page Overview 21 Oct Tuesday 1500 on REGISTRATION 1800 Welcome Reception & Cocktails at the Cape Town International Conference Centre (CTICC) 22 Oct Wednesday 0730 REGISTRATION 0830 OPENING 0900 PLENARY

More information

HOW RESEARCH INFLUENCES MS CARE TODAY? Patient Perspective Kimberly Haddock

HOW RESEARCH INFLUENCES MS CARE TODAY? Patient Perspective Kimberly Haddock HOW RESEARCH INFLUENCES MS CARE TODAY? Patient Perspective Kimberly Haddock My MS Story August 2011 - Life couldn't be better. 33 years old and finally on the happy trail of life New job as a clinical

More information

Understanding. Multiple Sclerosis. Tim, diagnosed in 2004.

Understanding. Multiple Sclerosis. Tim, diagnosed in 2004. Understanding Multiple Sclerosis Tim, diagnosed in 2004. What Is Multiple Sclerosis? Multiple sclerosis (MS) is a neurologic disorder that affects the central nervous system (CNS). The CNS includes the

More information

Errata Sheet ATOM Catalog 2014-2015

Errata Sheet ATOM Catalog 2014-2015 Errata Sheet ATOM Catalog 2014-2015 Pages 43-50 describing the Doctor of Acupuncture & Oriental Medicine (DAOM) Program are deleted in their entirety and replaced with the following: The Doctor of Acupuncture

More information

Vestibular Rehabilitation: A Competency-Based Course

Vestibular Rehabilitation: A Competency-Based Course Vestibular Rehabilitation: A Competency-Based Course Emory Conference Center and Hotel 1615 Clifton Road, NE Atlanta, Georgia 30329 Course Description This intense, evidence- based, six- day course is

More information

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market Launch of Several Pipeline Oral Products Could Diminish the Market for Injectable Therapies NEC3-52 November 2014 Contents

More information

7:00-9:30 PM Welcome reception- pool area

7:00-9:30 PM Welcome reception- pool area Scientific Program Clinical Advances in Neurology and Neuroscience 41 th Annual Meeting Southern Clinical Neurological Society Palm Beach Marriott Singer Island Beach Resort & Spa Riviera Beach, Florida

More information

Calendar of events NEUROLOGY

Calendar of events NEUROLOGY Calendar of events 2016 NEUROLOGY Rome, Italy 29 January 2016 Updates on MS treatment management Project an individualized treatment plan in MS Explain how to manage patients day to day issues List the

More information

The European Haemophilia Consortium (EHC) brings patients and patient organisations together from 44 European countries.

The European Haemophilia Consortium (EHC) brings patients and patient organisations together from 44 European countries. Printer Friendly Information EHC Conference in Belfast 3 rd, 4 th & 5 th October 2014 Introduction The European Haemophilia Consortium (EHC) brings patients and patient organisations together from 44 European

More information

Multiple Sclerosis Update. Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center

Multiple Sclerosis Update. Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center Multiple Sclerosis Update Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center None Disclosures First of All. Why is my talk in the Neurodegenerative hour? I respectfully object! Case

More information

Brooklyn Stroke Symposium 2015

Brooklyn Stroke Symposium 2015 Brooklyn Stroke Symposium 2015 May 28, 2015 Brooklyn Public Library Grand Army Plaza Sponsored by Keynote Presentations Sleep Apnea and Stroke: More than a Snore Devin L. Brown, M.D., M.S. Professor of

More information

National Multiple Sclerosis Symposium. 7-8 September 2015. Final Announcement. Berjaya Times Square Hotel Kuala Lumpur, Malaysia. Jointly organised by

National Multiple Sclerosis Symposium. 7-8 September 2015. Final Announcement. Berjaya Times Square Hotel Kuala Lumpur, Malaysia. Jointly organised by Final Announcement Jointly organised by National Multiple Sclerosis Symposium 7-8 September 2015 Berjaya Times Square Hotel Kuala Lumpur, Malaysia Department of Neurology Kuala Lumpur Hospital Malaysian

More information

Emergency Room Treatment of Psychosis

Emergency Room Treatment of Psychosis OVERVIEW The term Lewy body dementias (LBD) represents two clinical entities dementia with Lewy bodies (DLB) and Parkinson s disease dementia (PDD). While the temporal sequence of symptoms is different

More information

Vestibular Rehabilitation: A Competency-Based Course

Vestibular Rehabilitation: A Competency-Based Course Vestibular Rehabilitation: A Competency-Based Course Emory Conference Center and Hotel 1615 Clifton Road, NE Atlanta, Georgia 30329 Course Description This intense, evidence- based, six- day course is

More information

CBD Patient Survey. Care By Design. Fall

CBD Patient Survey. Care By Design. Fall Fall 15 CBD Patient Survey Care By Design DISCLAIMER: Care By Design products have not been evaluated by the Food and Drug Administration. The information herein is not intended to diagnose, treat or cure

More information

CHOREA, ATAXIA AND OTHER DYSKINESIAS

CHOREA, ATAXIA AND OTHER DYSKINESIAS Palacký University in Olomouc The Czech Movement Disorder Society INTERNATIONAL SYMPOSIUM CHOREA, ATAXIA AND OTHER DYSKINESIAS II. INFORMATION PALACKÝ UNIVERSITY ARTS CENTRE OLOMOUC, CZECH REPUBLIC November

More information

Physical Therapy Perspective on Ataxia. Roger Fong, MPT University of Chicago Medical Center March, 2010

Physical Therapy Perspective on Ataxia. Roger Fong, MPT University of Chicago Medical Center March, 2010 Physical Therapy Perspective on Ataxia Roger Fong, MPT University of Chicago Medical Center March, 2010 Definition: Physical Therapist Physical therapy dynamic profession with an established theoretical

More information

MULTIPLE SCLEROSIS. Megan Snyder INTRODUCTION TO EPIDEMOLOGY

MULTIPLE SCLEROSIS. Megan Snyder INTRODUCTION TO EPIDEMOLOGY MULTIPLE SCLEROSIS Megan Snyder INTRODUCTION TO EPIDEMOLOGY Snyder 1 Personal Connection to Multiple Sclerosis Multiple sclerosis (MS) is an extremely painful disease of which not enough is understood.

More information

Data include post-hoc assessments of controlled studies in relapsing MS regarding evolution of

Data include post-hoc assessments of controlled studies in relapsing MS regarding evolution of September 10, 2014 Contact: Shikha Virdi 905-919-0200 ext. 5504 EMD Serono Presents New Data on Rebif (Interferon beta-1a) and Multiple Sclerosis Pipeline at Joint ACTRIMS-ECTRIMS Meeting in Boston Data

More information

PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022. Multiple

PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022. Multiple Brochure More information from http://www.researchandmarkets.com/reports/2541548/ PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022 Description: PharmaPoint: Multiple

More information

2015 Diabetes Nursing Conference: Preventing, Treating, and Living with Complications

2015 Diabetes Nursing Conference: Preventing, Treating, and Living with Complications 2015 Diabetes Nursing Conference: Preventing, Treating, and Living with Complications February 26, 2015 Mayo Clinic Mayo Continuing Nursing Education General Information Conference description and goals

More information

Trauma Insurance Claims Seminar Invitation

Trauma Insurance Claims Seminar Invitation Trauma Insurance Claims Seminar Invitation Introduction Since the development of Trauma Insurance in Australia in the 1980s, the product has evolved at a great pace. Some of the challenges faced by claims

More information

International Symposium on: Pain and Cough

International Symposium on: Pain and Cough International Symposium on: Pain and Cough Florence (Italy), March 19-21, 2015 Organized by DEPARTMENT OF HEALTH SCIENCES DEPARTMENT OF EXPERIMENTAL AND CLINICAL MEDICINE UNIVERSITY OF FLORENCE DEPARTMENT

More information

Taylor Slotte Pathology Disease Report Spring 2014 Multiple Sclerosis

Taylor Slotte Pathology Disease Report Spring 2014 Multiple Sclerosis Taylor Slotte Pathology Disease Report Spring 2014 Multiple Sclerosis Abstract Multiple sclerosis (MS) is a chronic autoimmune disorder that attacks the body s central nervous system. It affects the brain,

More information

Alberta/Novartis Translational Research Fund Opportunity. Program Guide 2014/2015

Alberta/Novartis Translational Research Fund Opportunity. Program Guide 2014/2015 OBJECTIVES Program Guide 2014/2015 Alberta Innovates - Health Solutions (AIHS), Novartis Pharmaceuticals Canada Inc. (Novartis), and the Government of Alberta have partnered to create the Alberta/Novartis

More information

New Treatment Options for MS Patients: Understanding risks versus benefits

New Treatment Options for MS Patients: Understanding risks versus benefits New Treatment Options for MS Patients: Understanding risks versus benefits By Michael A. Meyer, MD Department of Neurology, Sisters Hospital, Buffalo, NY Objectives: 1. to understand fundamentals of MS

More information

APRN/PA Pediatric Updates in Clinical Practice

APRN/PA Pediatric Updates in Clinical Practice APRN/PA Pediatric Updates in Clinical Practice Monday, May 11, 2015 Considine Professional Building Auditorium 215 W. Bowery Street Akron, OH 44308 Conference Information Who Should Attend Nurse Practitioners,

More information

Lemtrada (alemtuzumab)

Lemtrada (alemtuzumab) Lemtrada (alemtuzumab) Policy Number: 5.02.517 Last Review: 08/2015 Origination: 08/2015 Next Review: 08/2016 Policy BCBSKC will provide coverage for Lemtrada (alemtuzumab) when it is determined to be

More information

Medication Policy Manual. Topic: Gilenya, fingolimod Date of Origin: November 22, 2010

Medication Policy Manual. Topic: Gilenya, fingolimod Date of Origin: November 22, 2010 Medication Policy Manual Policy No: dru229 Topic: Gilenya, fingolimod Date of Origin: November 22, 2010 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January

More information

A blood sample will be collected annually for up to 2 years for JCV antibody testing.

A blood sample will be collected annually for up to 2 years for JCV antibody testing. Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:

More information

CORPORATE SUPPORT OPPORTUNITIES

CORPORATE SUPPORT OPPORTUNITIES 29 th Milan Italy 2015 29th 29th INTERNATIONAL CONFERENCE OF OF AGRICULTURAL ECONOMISTS UNIVERSITÀ DEGLI STUDI DI DI MILANO, AUGUST 8-914 - 14 MILAN, ITALY A G R I C U L T U R E I N A N I N T E R C O N

More information

Cachexia and Nutrition in Advanced Cancer Patients: a Multidisciplinary Approach Chairs: M.S. Aapro, CH J. Herrstedt, DK F.

Cachexia and Nutrition in Advanced Cancer Patients: a Multidisciplinary Approach Chairs: M.S. Aapro, CH J. Herrstedt, DK F. REPORT Cachexia and Nutrition in Advanced Cancer Patients: a Multidisciplinary Approach Chairs: M.S. Aapro, CH J. Herrstedt, DK F. Strasser, CH 13-14 March 2015 Barcelona, Spain The Conference Cachexia

More information

Treatment of Steroid Unresponsive Relapse With Plasma Exchange in Aggressive Multiple Sclerosis

Treatment of Steroid Unresponsive Relapse With Plasma Exchange in Aggressive Multiple Sclerosis tap_794 298..302 Therapeutic Apheresis and Dialysis 14(3):298 302 doi: 10.1111/j.1744-9987.2009.00794.x Treatment of Steroid Unresponsive Relapse With Plasma Exchange in Aggressive Multiple Sclerosis Mario

More information

Neurotoxin and Headache Update

Neurotoxin and Headache Update Neurological Center for Pain in joint sponsorship with the Ohio Headache Association and Ohio Neurotoxin Association Present Neurotoxin and Headache Update October 11-12, 2013 Neurotoxin and Headache Update

More information

NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum

NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum OVERVIEW OF THE FELLOWSHIP The goal of the AASLD NP/PA Fellowship is to provide a 1-year postgraduate hepatology training program for nurse practitioners and physician assistants in a clinical outpatient

More information

15 TH EULAR POSTGRADUATE COURSE

15 TH EULAR POSTGRADUATE COURSE 15 TH EULAR POSTGRADUATE COURSE 12 15 October 2014 Prague, Czech Republic ORGANISATION AND COMMITTEE Scientific organiser Professor Ingrid Lundberg, Stockholm, Sweden Chairperson EULAR standing Committee

More information

Multiple Sclerosis: An imaging review and update on new treatments.

Multiple Sclerosis: An imaging review and update on new treatments. Multiple Sclerosis: An imaging review and update on new treatments. Dr Marcus Likeman Consultant Neuroradiologist North Bristol NHS Trust Bristol Royal Hospital for Children MRI appearances - White Matter

More information

NURSE PRACTITIONER PROGRAM THE PENNSYLVANIA STATE UNIVERSITY College of Nursing

NURSE PRACTITIONER PROGRAM THE PENNSYLVANIA STATE UNIVERSITY College of Nursing NURSE PRACTITIONER PROGRAM THE PENNSYLVANIA STATE UNIVERSITY College of Nursing Preceptor Evaluation of Student Clinical Performance: Adult Gerontology Acute Care Nurse Practitioner Option Nursing 863

More information

5.07.04. Provigil Nuvigil. Provigil (modafinil) / Nuvigil (armodafinil) Description. Section: Prescription Drugs Effective Date: July 1, 2015

5.07.04. Provigil Nuvigil. Provigil (modafinil) / Nuvigil (armodafinil) Description. Section: Prescription Drugs Effective Date: July 1, 2015 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.04 Subject: Provigil Nuvigil Page: 1 of 6 Last Review Date: June 19, 2015 Provigil Nuvigil Description

More information

2.1 Who first described NMO?

2.1 Who first described NMO? History & Discovery 54 2 History & Discovery 2.1 Who first described NMO? 2.2 What is the difference between NMO and Multiple Sclerosis? 2.3 How common is NMO? 2.4 Who is affected by NMO? 2.1 Who first

More information

Treatment Optimization in MS: When to Start, When to Shift, when to Stop

Treatment Optimization in MS: When to Start, When to Shift, when to Stop Treatment Optimization in MS: When to Start, When to Shift, when to Stop Mark S. Freedman MSc MD FAAN FANA FRCPC Director, Multiple Sclerosis Research Unit University of Ottawa Sr. Scientist, Ottawa Hospital

More information

October 23 25, 2014 Renaissance Orlando at SeaWorld, Florida

October 23 25, 2014 Renaissance Orlando at SeaWorld, Florida THE 1ST INTERNATIONAL SYMPOSIUM ON TECHNOLOGIES THAT ENHANCE CLINICAL OUTCOMES October 23 25, 2014 Renaissance Orlando at SeaWorld, Florida Jonathan Ferencz, Scientific Chair Speakers Michael Bergler Markus

More information

Collaborative Network Award Planning Grants Project Summaries

Collaborative Network Award Planning Grants Project Summaries Collaborative Network Award Planning Grants Project Summaries PRIORITY AREA: Projects that will drive development of one or more pre-clinical drug candidates through identification and validation of molecular

More information

Management of Concussion/Mild Traumatic Brain Injury - Evidence Based Practice

Management of Concussion/Mild Traumatic Brain Injury - Evidence Based Practice Management of Concussion/Mild Traumatic Brain Injury - Evidence Based Practice Introduction 1) The Centers for Disease Control and Prevention has estimated that each year, approximately Americans survive

More information